Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of March 2024, with a report date of March 26, 2024. The document serves as a transaction notification regarding a sale of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a regulatory disclosure of a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Sale of Ordinary Shares |
| Instrument | Ordinary shares of 31 1/4 pence each (ISIN: GB0009252882) |
| Volume | 3,551 shares |
| Price per Share | £16.8719 |
| Transaction Date | March 25, 2024 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
The filing does not report material changes to the company's financial position or operations. It discloses a reduction in the shareholding of Sally Jackson, SVP, Global Communications & CEO Office, who sold 3,551 ordinary shares.
Guidance, Outlook, and Risks
The filing text does not provide guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the statutory notification of the PDMR transaction.
Key Facts for Investor Verification
- Verify the total shareholding of Sally Jackson post-transaction to assess insider sentiment.
- Confirm the transaction price of £16.8719 against the market price on March 25, 2024.
- Note that this filing contains no operational or financial results for the quarter or year.